<html>
<head>
</head>
<body>
<p><span style="font-size: small;"><b>Nuvilex, Inc. One Step Closer to
Testing Eli Lilly’s $1.4 Bil_lion Yearly in Progressed, Inoperable
Pancreas Can_cer Therapies</b></span></p>
<p><span style="font-size: small;">Eli Lilly’s (NYSE: LLY) drug,
Gemzar, the average single dr_ug for pancreas can_cer patients equates to
around $1.4-bi_llion each year to Eli Lilly. There is a lot at stake
in the future of Nuvilex, Inc.’s (OTCQB: NVLX) Phase III clinical
tests – for Eli Lilly, for Nuvilex and for can_cer patients who are
striving for a improved treatment than the present single agent “gold
standard.” </span></p>
<p><span style="font-size: small;">Everyone has to envisage with the
figures Nuvilex has by now put on the table in two independent Phase II
trials… that this is a head to head matchup that Nuvilex deeply
anticipates while Eli Lilly might be worried about the outcomes.
Nuvilex has generated superior outcomes when matched to past figures for
Gemzar, and now the entity is prepared to use real time, head to head data
to demonstrate its therapy is better than Eli Lilly’s.</span></p>
<p><span style="font-size: small;">If the outcomes found with
Nuvilex’s treatment are statistically superior to those achieved with
Gemzar, the entity’s therapy could replace Gemzar’s 17-year
hold as the single agent “gold standard” for the treatment of
this distressing dis_ease. This would plainly be great news for
patients suffering from the di_sease, and it would be bloc_kbuster news for
Nuvilex’s shareholders.</span><br /><br /><span style="font-size:
small;">5847 San Felipe, 17th Floor, Houston, Texas 77057 United
States</span><br /><br /><span style="font-size: small;">The use of
research materials circulated by the auth.or is done at your own risk. You
are encouraged to do your own research before making any investment
decision in regards to the secu rity discussed herein. The author has not
been rewarded by any entity in connection with the distribution of these
materials. You should presume that as of the date of this report or letter,
the author, possibly along with or through our owners, affiliates,
employees and/or consultants, (cooperatively referred to as the author) has
a position in all company shares (and/or options of the shares) covered
herein that is consistent with the position set forth in our report. In
connection with NVLX, the author has taken a long position. Following the
disbursement of any report or letter, the author intends to continue
engaging in trnsactns in the secu rity covered herein, and we may be long,
short, and/or neutral at any time hereafter regardless of our initial
position and we preserve the right to procure or trade all or part of our
position at any time without notice. This practice could end in our trading
securities at any time before, during, and/or after the disbursement of
this commercial report.</span><br /><br /><span style="font-size:
small;"><a
href="http://info.apropositodjiboutianap.net/unsubscribe.php?M=6588707&C=0a89a74737fe0ab850bde605efc11be4&L=54&N=2169">Discontinue
me from this newsletter</a></span></p>
<img
src="http://info.apropositodjiboutianap.net/open.php?M=6588707&L=54&N=2169&F=H&image=.jpg"
height="1" width="10"></body>
</html>